COVID-19-associated coagulopathy: a clinical case

Background. Comorbid patients with a new coronavirus disease (COVID-19) often have thrombosis or bleeding in different periods of the disease. Early diagnosis of these complications and adequate therapy of these patients are complicated due to the peculiarities of the disease in comorbidity. Anticoagulation regimens in patients with COVID-19 are still unclear. The protocol of efficacy and safety the intermediate or therapeutic dose of low-molecular-weight heparins  is not clear and complete. It is very important to organize an individual approach for correction of the anticoagulants doses, taking into account the coagulation tests and the activity of inflammatory markers.

Clinical case description. We report a 71-year-old white male with COVID-19 pneumonia. Acute respiratory distress syndrome and atrial fibrillation were diagnosed in ten days of the disease. Therapeutic anticoagulation was started upon the admission. As early as in the 20th day of the disease a gluteal hematoma developed. Hence, prophylactic regimen of anticoagulation was started, but the worsening of dyspnea at rest, decreasing in SpO2 values to 82% according to pulse oximetry, and thrombelastographic hypercoagulability were observed after two days of such anticoagulation treatment. The patient has been receiving daily low-molecular-weight heparins injections in therapeutic doses for the following two weeks, and then the doctors have switched him to new oral anticoagulants. Patient was discharged to continue ambulatory anticoagulant’s treatment.

Conclusion. It is clear that the optimal choice of anticoagulation strategy in comorbid patients with concomitant COVID-19 remains challenging and requires randomized trials. Until the guidelines develop the effective anticoagulation strategy for various phenotypes of COVID-19 patients, the clinicians’ knowledge, experience and creative thinking will be apply to choose effective anticoagulant’s treatment on individual basis.

1. Miesbach W., Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin. Appl. Thromb. Hemost. 2020; 26: 1076029620938149. DOI: 10.1177/1076029620938149

2. Jayakrishnan T., Haag A., Mealy S., Minich C., Attah A., Turk M., Alrifai N., Alhuneafat L., Khoury F., Nasrullah A., Wedgeworth P., Mosley M., Vashistha K., Bakalov V., Chaturvedi A., Sangli S. Novel Coronavirus Infection (COVID-19) Related Thrombotic and Bleeding Complications in Critically Ill Patients: Experience from an Academic Medical Center. J. Clin. Med. 2021; 10(23): 5652. DOI: 10.3390/jcm10235652

3. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D., Kant K.M., Kaptein F.H.J., van Paassen J., Stals M.A.M., Huisman M.V., Endeman H. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb. Res. 2020; 191: 148–150. DOI: 10.1016/j.thromres.2020.04.041

4. Hanff T.C., Mohareb A.M., Giri J., Cohen J.B., Chirinos J.A. Thrombosis in COVID-19. Am. J. Hematol. 2020; 95(12): 1578–1589. DOI: 10.1002/ajh.25982

5. Huertas A., Montani D., Savale L., Pichon J., Tu L., Parent F., Guignabert C., Humbert M. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur. Respir. J. 2020; 56(1): 2001634. DOI: 10.1183/13993003.01634-2020

6. Rabaan A.A., Al-Ahmed S.H., Muhammad J., Khan A., Sule A.A., Tirupathi R., Mutair A.A., Alhumaid S., Al-Omari A., Dhawan M., Tiwari R., Sharun K., Mohapatra R.K., Mitra S., Bilal M., Alyami S.A., Emran T.B., Moni M.A., Dhama K. Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. Vaccines (Basel). 2021; 9(5): 436. DOI: 10.3390/vaccines9050436

7. Levi M. COVID-19 coagulopathy vs disseminated intravascular coagulation. Blood Adv. 2020; 4(12): 2850. DOI: 10.1182/bloodadvances.2020002197

8. Godino C., Scotti A., Maugeri N., Mancini N., Fominskiy E., Margonato A., Landoni G. Antithrombotic therapy in patients with COVID-19? Rationale and Evidence. Int. J. Cardiol. 2021; 324: 261–266. DOI: 10.1016/j.ijcard.2020.09.064

9. Altschul D.J., Unda S.R., de La Garza Ramos R., Zampolin R., Benton J., Holland R., Fortunel A., Haranhalli N. Hemorrhagic presentations of COVID-19: Risk factors for mortality. Clin. Neurol. Neurosurg. 2020; 198: 106112. DOI: 10.1016/j.clineuro.2020.106112

10. Rogani S., Calsolaro V., Franchi R., Calabrese A.M., Okoye C., Monzani F. Spontaneous muscle hematoma in older patients with COVID-19: two case reports and literature review. BMC Geriatr. 2020; 20(1): 539. DOI: 10.1186/s12877-020-01963-4

11. Castro R.A., Frishman W.H. Thrombotic Complications of COVID-19 Infection: A Review. Cardiol. Rev. 2021; 29(1): 43–47. DOI: 10.1097/CRD.0000000000000347

12. Musoke N., Lo K.B., Albano J., Peterson E., Bhargav R., Gul F., DeJoy R. 3rd, Salacup G., Pelayo J., Tipparaju P., Azmaiparashvili Z., Patarroyo-Aponte G., Rangaswami J. Anticoagulation and bleeding risk in patients with COVID-19. Thromb. Res. 2020; 196: 227–230. DOI: 10.1016/j.thromres.2020.08.035

13. Yu J.Z., Granberg T., Shams R., Petersson S., Sköld M., Nyrén S., Lundberg J. Lung perfusion disturbances in nonhospitalized post-COVID with dyspnea-A magnetic resonance imaging feasibility study. J. Intern. Med. 2022; 292(6): 941–956. DOI: 10.1111/joim.13558

14. Abate V., Casoria A., Rendina D., Muscariello R., Nuzzo V., Vargas M., Servillo G., Venetucci P., Conca P., Tufano A., Galletti F., Di Minno G. Spontaneous Muscle Hematoma in Patients with COVID-19: A Systematic Literature Review with Description of an Additional Case Series. Semin. Thromb. Hemost. 2022; 48(1): 100–108. DOI: 10.1055/s-0041-1732370

15. Nadkarni G.N., Lala A., Bagiella E., Chang H.L., Moreno P.R., Pujadas E., Arvind V., Bose S., Charney A.W., Chen M.D., Cordon-Cardo C., Dunn A.S., Farkouh M.E., Glicksberg B.S., Kia A., Kohli-Seth R., Levin M.A., Timsina P., Zhao S., Fayad Z.A., Fuster V. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. J. Am. Coll. Cardiol. 2020; 76(16): 1815–1826. DOI: 10.1016/j.jacc.2020.08.041

16. Boira I., Esteban V., Vañes S., Castelló C., Celis C., Chiner E. Major Bleeding Complications in COVID-19 Patients. Cureus. 2021; 13(8): e16816. DOI: 10.7759/cureus.16816

17. Sholzberg M., Tang G.H., Negri E., Rahhal H., Kreuziger L.B., Pompilio C.E., James P., Fralick M., AlHamzah M., Alomran F., Tseng E., Lim G., Lillicrap D., Carrier M., Áinle F.N., Beckett A., da Costa B.R., Thorpe K., Middeldorp S., Lee A., Cushman M., Jüni P. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG — RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021; 22(1): 202. DOI: 10.1186/s13063-021-05076-0